Programs Pipeline

Sirona Biochem / TFChem, specialize in the improvement and development of carbohydrate-based molecules through fluorination. Carbohydrate-based molecules offer immense commercial potential for cosmetics and therapeutics. Sirona is currently focused on advancing three programs –cosmetic agents, therapeutics and biological ingredients.  The two most advanced programs include the  cosmetic skin lightener  and diabetes drug. Other ongoing projects include the development and commercial opportunities for the Glycoprotein library and the synthesis of a compound for acne treatment.

Sirona Biochem has made significant advancements in the area of skin lightening. Recognized for scientific innovation at the laboratory in France, the French government awarded the Company an innovation grant worth CDN$1.9 Million to develop the cosmetic skin lightener program to a commercial ready stage.  Since then, numerous efficacy and stability studies have been completed with results showing superiority over popular commercial products.  In 2014, Sirona and Obagi Medical Products (Obagi) executed a global exclusive licensing agreement for the commercialization of skin lightening compound TFC-849. Sirona Biochem received a licensing fee and will receive ongoing royalty payments for global product sales from Obagi Medical Products. As of September 2017,  TFC-849 will be transferred with the sale of Obagi to Haitong International Zhonghua Finance Acquisition Fund I LP.


In addition to TFC-849, the Company has a library of skin lightening compounds and remains in partnering discussions for the compound TFC-1067. In parallel, we are further expanding and developing the rest of our skin-lightening portfolio.

The sodium glucose co-transporter (SGLT) inhibitor for diabetes, achieved positive preclinical results. In a head-to-head preclinical study, Sirona Biochem’s SGLT inhibitor performed better than Johnson and Johnson’s canagliflozin (Invokana™), which was given FDA market approval in the U.S. (March 2013) and in Europe (November 2013).  In 2014, Sirona licensed the SGLT2 Inhibitor to Wabang Biopharmaceuticals for development and commercialization of this anti-diabetic inhibitor exclusively in the People’s Republic of China (PRC). In exchange for this license, Wanbang Biopharma has provided an upfront and will give milestone payments of up to US$9.5M in addition to royalty payments for product sales. Following positive in-vivo studies, Wanbang expects to file the IND to the CFDA by the end of 2017. This will trigger another milestone payment of $500,000 USD to Sirona.  

Extensive research and development is currently underway for the Glycoprotein library. These compounds have shown a role in protection of cells under different stressors, including UV, starvation and oxidative conditions. The lab at TFChem and several CROs are performing assays and analyses of the compounds to move them towards commercialization. Current cosmetic indications of the portfolio include keloid and stress protection creams, along with a potential role as an adjuvant in cell preservation solutions.

Finally, TFChem has been diligently working on the synthesis of a compound in acne treatments. Several of the compounds have completed chemistry and anticipate preclinical testing in Q4 2017.

Sirona Biochem’s proprietary chemistry technology has relevance in many therapeutic, cosmetic and biological areas where the potential for development is high.


Product Development

While carbohydrate-based molecules offer immense commercial potential, we are focusing on three programs at this time.